Evidence Hub

A long noncoding RNA regulates in vitro and in vivo triazole antifungal susceptibility in Aspergillus fumigatus

Poudyal NR, Mehlem RT, Doneparthi P, Cady TL, Kaufman G, Willger SD, Ortiz M, Noorai RE et al.

Genetics, 2026

1 citation

Abstract

Azole-resistant Aspergillus infections are a source of increasing concern with limited alternative therapeutic options. However, as most infections are still caused by azole-susceptible Aspergillus strains, there is a need to better understand fungal responses to azole antifungals. To this end, we discover that a long noncoding RNA, afu-182, is a major regulator of cyp51-independent sub-minimum inhibitory concentration (MIC) azole response. We observe that the loss of afu-182 leads to increased surface-attached growth and poorer disease outcomes in a murine model of invasive pulmonary aspergillosis upon azole treatment. In contrast, OE of afu-182 significantly reduces fungal burden in animals treated with the azole drug posaconazole. Importantly, afu-182 levels decrease upon azole exposure, and in an azole adaptation experiment, continuous exposure to low-dose azole led to MIC increase in an afu-182-dependent manner. Whole transcriptome analyses revealed that azole drug treatment leads to an increase in transcripts of genes encoding 7-transmembrane domain proteins of the RTA1 family, and these proteins are negatively regulated by afu-182. Two RTA1 family genes have individual and combined effects and are sufficient to increase fungal susceptibility to azole drugs in the wildtype (WT) strain. Taken together, our data show a role of the long noncoding RNA afu-182 in regulating Aspergillus fumigatus response to azole drugs both in vitro and in vivo.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free